COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse : Sanofi et CD&R s’allient pour soutenir les ambitions d’Opella dans la santé grand public

21/10/2024 - 07:30

Sanofi et CD&R s’allient pour soutenir les ambitions d’Opella dans la santé grand public Sanofi et CD&R entrent en négociations exclusives pour le transfert d’une participation de contrôle de 50 % dans Opella ; [...]

ONWARD® Medical Announces Changes to Board of Directors, Including Addition of Medtech Leader Rob ten Hoedt as Incoming Chairman

21/10/2024 - 07:30

Ten Hoedt is a former Medtronic President and Executive Committee Member; also a former Chairman of MedTech Europe Commercial and digital health expert Rahma Samow will also join as Director Current Board Chairman Jan [...]

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

21/10/2024 - 06:00

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-01 1 , a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases [...]

KFSHRC Leads the Way in AI-Powered Diagnostics and Minimally Invasive Surgeries

20/10/2024 - 18:21

RIYADH, Saudi Arabia, Oct. 20, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) continues to contribute to advancing healthcare through pioneering advancements in AI-driven [...]

Le KFSHRC, pionnier du traitement du cancer grâce à ses thérapies novatrices et ses résultats exceptionnels

20/10/2024 - 15:18

RIYAD, Arabie saoudite, 20 oct. 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (« KFSHRC ») révolutionne le traitement du cancer dans la région grâce à des thérapies transformatrices [...]

KFSHRC Pioneers Cancer Treatment with Breakthrough Therapies and Exceptional Outcomes

19/10/2024 - 14:14

RIYADH, Saudi Arabia, Oct. 19, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is revolutionizing cancer treatment in the region with transformative therapies like CAR-T cell [...]

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

19/10/2024 - 14:00

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial Responses are durable and deepen over time [...]

Le KFSHRC impose son leadership en matière de veille dans les soins de santé pour le diagnostic et les soins aux patients

19/10/2024 - 13:16

RIYAD, Arabie Saoudite, 19 oct. 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSHRC) contribue à l’innovation mondiale en matière de soins de santé, en tirant parti de l’ [...]

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

19/10/2024 - 05:00

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

19/10/2024 - 04:46

WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified [...]

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

19/10/2024 - 00:00

FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc . (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that [...]

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

18/10/2024 - 23:05

88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the Phase 3 PHOTON [...]

Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study

18/10/2024 - 23:00

The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema (DME) treated with Vabysmo who identify as African American, Black, Hispanic and [...]

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18/10/2024 - 22:31

DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee [...]

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

18/10/2024 - 22:30

Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical [...]

DBV Technologies participera au prochain congrès de l'ACAAI 2024

18/10/2024 - 22:30

Châtillon, France, le 18 octobre (22 :30 CEST) 2024 DBV Technologies participera au prochain congrès de l'ACAAI 2024 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT), société [...]

Globus Medical to Participate in Orthopedic Trauma Association Annual Meeting

18/10/2024 - 22:30

AUDUBON, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, is participating in the 40 th Annual Meeting of the Orthopedic Trauma Association (OTA) in [...]

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18/10/2024 - 22:30

NOVATO, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

18/10/2024 - 22:01

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced [...]